Tenofovir Emtricitabine is a fixed-dose combination tablet that contains Tenofovir Disoproxil (300 mg) and Emtricitabine (200 mg). It belongs to the therapeutic class HIV Management and is used as part of antiretroviral therapy (ART) for people living with HIV-1 and as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV. In Hong Kong, the product is prescription-only and is regulated by the Department of Health under the Pharmacy and Poisons Ordinance.
Tenofovir Disoproxil and Emtricitabine are both nucleos(t)ide reverse transcriptase inhibitors (NRTIs). After oral absorption, Tenofovir Disoproxil is converted to the active diphosphate form, which mimics deoxyadenosine and becomes incorporated into viral DNA. This incorporation terminates the DNA chain, preventing the HIV reverse transcriptase enzyme from synthesizing new viral genomes.
Emtricitabine follows a similar pathway: it is phosphorylated to its active triphosphate, which competes with the natural nucleoside cytidine. Once incorporated, it also halts DNA elongation.
Together, the two agents provide a synergistic blockade of reverse transcription, leading to rapid reduction of plasma HIV RNA levels. Onset of antiviral activity occurs within hours of the first dose, with peak intracellular concentrations typically reached after 4-6 hours. The combined tablet maintains effective intracellular drug levels for 24 hours, supporting once-daily dosing.
These indications are approved by the Hong Kong Department of Health and align with international regulatory approvals (FDA, EMA).
Research has examined Tenofovir Emtricitabine for hepatitis B virus (HBV) suppression because Tenofovir possesses activity against HBV polymerase. However, Tenofovir Emtricitabine is not approved for HBV monotherapy in Hong Kong, and off-label use would require careful medical supervision. No other off-label indications have sufficient peer-reviewed evidence to warrant inclusion.
Absolute contraindications
Relative contraindications
Special populations
Note: Patients should disclose all prescription, over-the-counter, herbal, and dietary supplement use to their healthcare provider before starting Tenofovir Emtricitabine.
Patients should contact their healthcare provider promptly if they notice new swelling, decreased urine output, unexplained weight loss, or persistent gastrointestinal symptoms.
This article provides educational information about Tenofovir Emtricitabine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. It is commonly combined with a third agent such as an integrase inhibitor or a protease inhibitor to form a complete regimen. However, specific drug-drug interactions (e.g., with didanosine or certain protease inhibitors) must be reviewed by a clinician to avoid toxicity.
Report symptoms such as swelling, decreased urine output, or unexplained fatigue to your healthcare provider immediately. Laboratory tests will assess renal function, and the provider may adjust the dose or switch to an alternative regimen.
Tenofovir has activity against hepatitis B virus, but the combination tablet is not approved for HBV monotherapy in Hong Kong. Patients with HBV co-infection typically remain on Tenofovir-containing regimens under specialist supervision.
In Hong Kong, the 300/200 mg tablet is usually round, bicolored (often white with a blue imprint), and bears the imprint code “TAF/FTC 300/200” (or a manufacturer-specific code). Always verify the imprint against the pharmacy label.
Standard workplace drug screens do not test for antiretrovirals, so Tenofovir Emtricitabine will not trigger a positive result. However, specific clinical trials or forensic testing that includes antiretroviral detection could identify the drug.
Yes, but carry the medication in its original packaging with a copy of the prescription. Some countries require a doctor’s letter confirming the need for continuous HIV therapy; check the destination’s entry requirements before travel.
Limited data suggest low levels of Tenofovir and Emtricitabine are present in breast milk. The Hong Kong guidance advises weighing the benefits of maternal viral suppression against potential infant exposure; a specialist should make the recommendation.
Tenofovir Alafenamide (TAF) delivers a higher intracellular concentration with lower systemic exposure, resulting in reduced renal and bone toxicity. Both provide the same antiviral effect, but TAF may be preferred for patients at risk of kidney or bone complications.
When used as part of a fully suppressive ART regimen, most patients achieve an undetectable HIV-1 RNA level within 8-12 weeks. Individual response varies based on baseline viral load and adherence.
No specific dietary restrictions are required. Maintaining a balanced diet supports overall health and may help mitigate side effects such as nausea.
